EU PERSPECTIVES - Brussels is willing to accept higher costs for healthcare systems to win the global biotech race. A new EU incentive would extend intellectual property rights for a handful of cutting-edge drugs, delaying cheaper biosimilars at an estimated €615 million a year. Europe is betting the trade-off will be worth it. Read more

EURACTIV - Belgian biopharma firm UCB has entered one of the most aggressive strategic expansion phases in its recent history, using acquisitions and partnerships across the United States, China and Europe to rapidly expand its biotechnology capabilities. Read more

EU PERSPECTIVES - Six years after COVID-19 upended the world, governments are still struggling to agree on how future pandemics should be handled. But the World Health Assembly also revealed a broader shift: global health policy is no longer focused only on responding to crises, but increasingly on preventing them before they spiral out of control....

EU PERSPECTIVES - The latest hantavirus outbreak is forcing Europe to confront an uncomfortable reality: vaccines or treatments against some dangerous viruses may never reach the market. Not because the science is impossible, but because developing them is not commercially attractive for pharmaceutical companies. Brussels is increasingly...

EURACTIV - Benoît van den Hove tells Euractiv that scaling biotech companies at a global level still depends on capital that Europe does not yet mobilise at sufficient scale. Read more

APM MARKET ACCESS - The European Council and the European Parliament have reached a provisional agreement on implementing tariff elements of the EU-U.S. Joint Statement, as pharmaceutical industry groups warn that continued uncertainty around transatlantic trade could disrupt drug supply chains and increase pressure on smaller innovative companies....

EURACTIV - Healthcare is increasingly being asked to square a difficult circle: deliver care without contributing to the environmental pressures driving disease in the first place. At the same time, systems are being pushed to shift from treatment to prevention as the basis for long-term sustainability. Read more

EU PERSPECTIVES - Europe prides itself on universal healthcare, yet patients still wait hundreds of days—sometimes even years—for access to new medicines. EU Health Commissioner Olivér Várhelyi is openly warning that without faster approvals, quicker reimbursement decisions and stronger pharmaceutical production in Europe, the continent's...

APM MARKET ACCESS - Europe is falling further behind the U.S. and risks losing ground to China in access to innovative drugs, while patients across the continent continue to face widening inequalities and longer delays to treatment, according to the latest "Patients Waiting to Access Innovative Therapies" (W.A.I.T.) Indicator published on...

EU PERSPECTIVES - The next disease outbreak could reach Europe before anyone has a name for it. Washington's withdrawal from the World Health Organization has pushed the global health system into one of its deepest crises in decades, and Brussels is moving in. The European Commission's new global health strategy stakes Europe's claim as the anchor...